# Edesa Biotech, Inc.: financial statements, quarterly

EDSA · Nasdaq · CIK 1540159 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/edsa.md) · [Financials](/companies/edsa/financials.md) · [Filings](/companies/edsa/filings.md) · [Insiders](/companies/edsa/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/edsa/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [953 d](/filings/0001171843-24-006946.md) | [704](/filings/0001171843-25-000866.md) | [1,176](/filings/0001171843-25-003189.md) | [897](/filings/0001171843-25-005236.md) | [104 d](/filings/0001171843-25-007914.md) | [1,020](/filings/0001171843-26-000812.md) | [484](/filings/0001171843-26-003433.md) | [939](/filings/0001171843-26-005502.md) | [1,226 d](/filings/0001171843-25-007914.md) | [1,125](/filings/0001171843-26-000812.md) | [2,767](/filings/0001171843-26-003433.md) | [3,958](/filings/0001171843-26-005502.md) |
| Operating income | $k | [(2,370) d](/filings/0001171843-24-006946.md) | [(1,857)](/filings/0001171843-25-000866.md) | [(2,220)](/filings/0001171843-25-003189.md) | [(1,932)](/filings/0001171843-25-005236.md) | [(1,004) d](/filings/0001171843-25-007914.md) | [(1,899)](/filings/0001171843-26-000812.md) | [(1,639)](/filings/0001171843-26-003433.md) | [(1,904)](/filings/0001171843-26-005502.md) | [(2,470) d](/filings/0001171843-25-007914.md) | [(2,341)](/filings/0001171843-26-000812.md) | [(4,297)](/filings/0001171843-26-003433.md) | [(5,520)](/filings/0001171843-26-005502.md) |
| Income tax | $k | [0.0 d](/filings/0001171843-24-006946.md) | not reported | [0.8](/filings/0001171843-25-003189.md) | [0.0](/filings/0001171843-25-005236.md) | [0.0 d](/filings/0001171843-25-007914.md) | not reported | [0.8](/filings/0001171843-26-003433.md) | [0.0](/filings/0001171843-26-005502.md) | [0.0 d](/filings/0001171843-25-007914.md) | not reported | [0.8](/filings/0001171843-26-003433.md) | [0.0](/filings/0001171843-26-005502.md) |
| Net income | $k | [(1,720) d](/filings/0001171843-24-006946.md) | [(1,678)](/filings/0001171843-25-000866.md) | [(1,861)](/filings/0001171843-25-003189.md) | [(1,668)](/filings/0001171843-25-005236.md) | [(962) d](/filings/0001171843-25-007914.md) | [(1,617)](/filings/0001171843-26-000812.md) | [(1,590)](/filings/0001171843-26-003433.md) | [(1,749)](/filings/0001171843-26-005502.md) | [(2,228) d](/filings/0001171843-25-007914.md) | [(2,248)](/filings/0001171843-26-000812.md) | [(4,218)](/filings/0001171843-26-003433.md) | [(5,408)](/filings/0001171843-26-005502.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | not reported | [(0.54)](/filings/0001171843-25-000866.md) | [(0.58)](/filings/0001171843-25-003189.md) | [(0.52)](/filings/0001171843-25-005236.md) | not reported | [(0.48)](/filings/0001171843-26-000812.md) | [(0.30)](/filings/0001171843-26-003433.md) | [(0.25)](/filings/0001171843-26-005502.md) | not reported | [(0.28)](/filings/0001171843-26-000812.md) | [(0.49)](/filings/0001171843-26-003433.md) | [(0.60)](/filings/0001171843-26-005502.md) |

- Revenue: not reported
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.4](/filings/0001654954-23-015632.md) | not reported | not reported | not reported | [1.0](/filings/0001171843-24-006946.md) | [1.6](/filings/0001171843-25-000866.md) | [13.9](/filings/0001171843-25-003189.md) | [12.4](/filings/0001171843-25-005236.md) | [10.8](/filings/0001171843-25-007914.md) | [12.1](/filings/0001171843-26-000812.md) | [10.0](/filings/0001171843-26-003433.md) | [10.3](/filings/0001171843-26-005502.md) |
| Current assets | $m | [6.4](/filings/0001171843-24-006946.md) | [5.4](/filings/0001654954-24-001540.md) | [4.2](/filings/0001654954-24-005971.md) | [3.0](/filings/0001171843-24-004651.md) | [1.7](/filings/0001171843-25-007914.md) | [2.1](/filings/0001171843-25-000866.md) | [14.4](/filings/0001171843-25-003189.md) | [12.8](/filings/0001171843-25-005236.md) | [11.5](/filings/0001171843-26-005502.md) | [12.7](/filings/0001171843-26-000812.md) | [10.4](/filings/0001171843-26-003433.md) | [10.8](/filings/0001171843-26-005502.md) |
| Total assets | $m | [8.9](/filings/0001171843-24-006946.md) | [7.8](/filings/0001654954-24-001540.md) | [6.5](/filings/0001654954-24-005971.md) | [5.2](/filings/0001171843-24-004651.md) | [3.8](/filings/0001171843-25-007914.md) | [4.2](/filings/0001171843-25-000866.md) | [16.5](/filings/0001171843-25-003189.md) | [14.8](/filings/0001171843-25-005236.md) | [13.5](/filings/0001171843-26-005502.md) | [14.7](/filings/0001171843-26-000812.md) | [12.4](/filings/0001171843-26-003433.md) | [12.7](/filings/0001171843-26-005502.md) |
| Current liabilities | $m | [1.8](/filings/0001171843-24-006946.md) | [2.0](/filings/0001654954-24-001540.md) | [2.2](/filings/0001654954-24-005971.md) | [2.4](/filings/0001171843-24-004651.md) | [1.8](/filings/0001171843-25-007914.md) | [1.9](/filings/0001171843-25-000866.md) | [0.9](/filings/0001171843-25-003189.md) | [0.7](/filings/0001171843-25-005236.md) | [1.1](/filings/0001171843-26-005502.md) | [0.8](/filings/0001171843-26-000812.md) | [2.2](/filings/0001171843-26-003433.md) | [3.9](/filings/0001171843-26-005502.md) |
| Total liabilities | $m | [1.8](/filings/0001171843-24-006946.md) | [2.0](/filings/0001654954-24-001540.md) | [2.2](/filings/0001654954-24-005971.md) | [2.4](/filings/0001171843-24-004651.md) | [1.8](/filings/0001171843-24-006946.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [7.0](/filings/0001171843-25-007914.md) | [5.8](/filings/0001171843-25-003189.md) | [4.3](/filings/0001171843-25-005236.md) | [2.9](/filings/0001171843-25-005236.md) | [2.0](/filings/0001171843-26-005502.md) | [2.3](/filings/0001171843-26-003433.md) | [15.5](/filings/0001171843-26-005502.md) | [14.1](/filings/0001171843-26-005502.md) | [12.5](/filings/0001171843-26-005502.md) | [14.0](/filings/0001171843-26-003433.md) | [10.2](/filings/0001171843-26-005502.md) | [8.8](/filings/0001171843-26-005502.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,468) d](/filings/0001171843-24-006946.md) | [(1,407)](/filings/0001171843-25-000866.md) | [(1,660) d](/filings/0001171843-25-003189.md) | [(856) d](/filings/0001171843-25-005236.md) | [(967) d](/filings/0001171843-25-007914.md) | [(1,517)](/filings/0001171843-26-000812.md) | [(2,383) d](/filings/0001171843-26-003433.md) | [(1,701) d](/filings/0001171843-26-005502.md) | [(1,721) d](/filings/0001171843-25-007914.md) | [(2,087)](/filings/0001171843-26-000812.md) | [(2,017) d](/filings/0001171843-26-003433.md) | [(3,083) d](/filings/0001171843-26-005502.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001654954-23-015632.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2013-12-31) | period not labelled (2014-03-31) | period not labelled (2014-06-30) | Q1 FY2015 (2014-12-31) | Q2 FY2015 (2015-03-31) | Q3 FY2015 (2015-06-30) | Q3 FY2016 (2016-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [74.0](/filings/0001144204-15-007126.md) | [76.2](/filings/0001144204-15-029347.md) | [86.9](/filings/0001144204-15-047755.md) | [79.5](/filings/0001144204-15-007126.md) | [79.5](/filings/0001144204-15-029347.md) | [8.5](/filings/0001144204-16-117445.md) | [8.4](/filings/0001144204-16-117445.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,641,031 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001171843-26-005502.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.